Short-term lipid changes associated with highly active antiretroviral therapy in naive HIV-infected patients [5]

Journal of Acquired Immune Deficiency Syndromes

Volumn 34, Issue 2, 2003, Pages 249-251

  Palacios, Rosario ^a   Santos, Jesús ^a   Ruiz, Josefa ^a   González, Mercedes ^a   Valdivielso, Pedro ^a   Márquez, Manuel ^a   González Santos, Pedro ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DYSLIPIDEMIA; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; LIPID BLOOD LEVEL; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PREVALENCE; PRIORITY JOURNAL; SIDE EFFECT; STATISTICAL ANALYSIS;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIV INFECTIONS; HUMANS; HYPERLIPIDEMIAS; LIPIDS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TIME FACTORS;

EID: 0141923754     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200310010-00021     Document Type: Letter

References (25)

1. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving PI. AIDS. 1998;12:F51-F58.
2. Tsiodras S, Mantzoros C, Hammer S, et al. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study. Arch Intern Med. 2000;160: 2050-2056.
3. Martinez E, Mocroft A, García-Viejo MA, et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet. 2001;357:592-598.
4. Heath KV, Hogg RS, Chan KJ, et al. Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database. AIDS. 2001;15:231-239.
5. Thiébaut R, Daucourt V, Mercié P, et al. Lipodystrophy, metabolic disorders, and human immunodeficiency infection: Aquitaine Cohort, France, 1999. Clin Infect Dis. 2000;31:1482-1487.
6. Mallal SA, John M, Moore CB, et al. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS. 2000;14: 1309-1316.
7. Carr A, Miller J, Law M, et al. Syndrome of lipoatrophy, lactic acidaemia and liver disfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS. 2000; 14:F25-F32.
8. Magde S, Kinloch-de-Loes S, Mercey D, et al. Lipodystrophy in patients naïve to HIV protease inhibitors. AIDS. 1999;13:735-737.
9. Saint-Marc T, Partisani M, Poizot-Martin I, et al. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study. AIDS. 2000;14:37-49.
10. Safrin S, Grunfeld C. Fat distribution and metabolic changes in patients with HIV infection. AIDS. 1999;13:2493-2505.
11. Vergis EN, Paterson DL, Wagener MM, et al. Dyslipidaemia in HIV-infected patients: association with adherence to potent antiretroviral therapy. Int J STD AIDS. 2001;12:463-468.
12. Pernestorfer-Schoen H, Jilma B, Perschler A, et al. Sex differences in HAART-associated dyslipidaemia. AIDS. 2001;15:725-734.
13. National Cholesterol Education Program. Summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on the Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;10: 299-313.
14. 2) and triceps skin-fold thickness. Am J Clin Nutr. 1991;53:839-846.
15. Dong KL, Bausserman LL, Flynn MM, et al. Changes in body habitus and serum lipid abnormalities in HIV-positive women on highly active antiretroviral therapy (HAART). J Acquir Immune Defic Syndr. 1999;21:107-113.
16. Stein JH, Klein MA, Bellehumeur JL, et al. Use of human immunodeficiency virus-1 protease inhibitors associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation. 2001;104:257-262.
17. Berthold HK, Parhofer KG, Ritter MM, et al. Influence of protease inhibitors on lipoprotein metabolism. J Intern Med. 1999;246:567-575.
18. Wanke CA. Epidemiological and clinical aspects of the metabolic complications of HIV infection: the fat redistribution syndrome. Editorial review. AIDS. 1999;13:1287-1293.
19. Segarra-Newnham M. Hyperlipidemia in HIV-positive patients receiving antiretrovirals. Ann Pharmacother. 2002;36:592-595.
20. Van der Valk M, Kastelein JJP, Murphy RL, et al., on behalf of the Atlantic Study team. Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an antiatherogenic lipid profile. AIDS. 2001;15: 2407-2414.
21. Carr A, Hudson J, Chuah J, et al. HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study. AIDS. 2001;15:1811-1822.
22. Grunfeld C, Pang M, Doerrler W, et al. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency syndrome. J Clin Endocrinol Metab. 1992;74:1045-1052.
23. Constans J, Pellegrin JL, Peuchant E, et al. High plasma lipoprotein (a) in HIV-positive patients. Lancet. 1993;341:1099-1100.
24. Smith KY. Selected metabolic and morphologic complications associated with highly active antiretroviral therapy. J Infect Dis. 2002;185(suppl 2):S123-S127.
25. Savès M, Raffi F, Capeau J, et al., and the Antiprotéases Cohorte (APROCO) Study Group. Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy. Clin Infect Dis. 2002;34: 1396-1405.